Combined Anticancer Treatment of Advanced Colon Cancer

Phase 2 Terminated 26 enrolled University of Regensburg Heinrich-Heine University, Duesseldorf · collab

NaSingle-groupOpen-labelTreatment

Summary

The COMBATAC study evaluates the the effect as assessed by progression-free survival (PFS) of perioperative systemic chemotherapy including cetuximab and cytoreductive surgery (CRS) and bidirectional hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal carcinomatosis arising from colorectal cancer.

Timeline

Start: 2010-10
Primary completion: 2015-09
Completion: 2017-10

Outcome

Outcome not reported

Stopped (Enrollment): “Slow recruitment.”

Publications

Background Glockzin G, Rochon J, Arnold D, Lang SA, Klebl F, Zeman F, Koller M, Schlitt HJ, Piso P. A prospective multicenter phase II study evaluating multimodality treatment of patients with peritoneal carcinomatosis arising from appendiceal and colorectal cancer: the COMBATAC trial. BMC Cancer. 2013 Feb 7;13:67. doi: 10.1186/1471-2407-13-67.
Results Glockzin G, Zeman F, Croner RS, Konigsrainer A, Pelz J, Strohlein MA, Rau B, Arnold D, Koller M, Schlitt HJ, Piso P. Perioperative Systemic Chemotherapy, Cytoreductive Surgery, and Hyperthermic Intraperitoneal Chemotherapy in Patients With Colorectal Peritoneal Metastasis: Results of the Prospective Multicenter Phase 2 COMBATAC Trial. Clin Colorectal Cancer. 2018 Dec;17(4):285-296. doi: 10.1016/j.clcc.2018.07.011. Epub 2018 Jul 31.

Drugs

Evaluation	Drug	Modality	Dose	Route
Background	Leucovorin	Small molecule	20 mg/m2	Intravenous
Background	Oxaliplatin	Small molecule	300 mg/m2	Other
Background	fluorouracil	Small molecule	400 mg/m2	Intravenous